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Abstract 
Outcome assessment has been used to evaluate the length of ueatment needed and has been 
disputed for some time. Changes within both mental health and health insurnnce companies have 
contributed to a trend toward time-limited therapy and the optimal number of sessions has 
become a cenual issue. This study sought to ex.tend research in the area of treatment outcome. 
Specifically. it examined the efficacy of psychotherapy after five and ten sessions on the 
subjective well-being of university students. 
Three hypotheses were tested in th.is study: (1) Subjective Well-Being scores (as measured 
by the Outcome Questionnaire-45. l l) for the treatment group will be significantly higher than 
those of the control group on the mid and post-tests. (2) Subjective Well-Being scores will be 
higher for the treatment group subjects tested after five, and ten sessions of individual 
psychotherapy than the scores of the same subjects on the pretest. (3) Subjective Well-Being 
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scores will be higher for the treatment group subjects tested after ten sessions than the scores of the 
same subjects after five sessions. The results did not support the three hypotheses as clinically 
significant change was not demonstrated. 
When time was compared to group and gender, there were interaction effects. There was a 
quadratic effect on the interpersonal Relationships scale and a quadratic effect was found when 
time. group and sex were compared on the Social Role Performance scale. Chi-square analyses 
were performed and the interpersonal Relationships scale, F(l,19)=3.446; p=.079, approached 
significance. Although there were no significant group effects found when the two treatment 
groups were compared, there were three quadratic effects and interaction effects. · 
Future dose-effect studies may benefit from taking their treatment group from a clinical 
s<1mple. Using a more diverse sample would also be a beuer representative of the greater 
population. ln addition, it is proposed that dose-effect studies examine the effects of more or less 
therapy for a particular problem and avoid seeking to show a particular treatment duration as 
optimal. 
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Outcome studies attempt to analyze the effects of psychotherapy and its potencial for 
alleviating different types of mental problems (Lindfors, et al., 1995). Outcome assessment has 
been practiced since the I 930's (Lambert, Okiishi, Finch, & Johnson, 1998) and has changed with 
the practice of psychology. Conte (1997) wrote 
Psychotherapy outcome research has evolved substantially, both conceptually and 
methodologically. since Eysenck's 1952 controversial evaluation of its effectiveness. Since 
the I 950's and early '60s, we have moved from the relatively unsophisticated question of 
whether psychotherapy of a nonspecific nature and applied to heterogeneous patient 
samples can effectively produce personality change to more complex. questions. (p. 445) 
Some of these more complex. questions have led to studies finding that psychotherapy can lead to a 
decrease in utilization of medical care following psychotherapy (Gabbard, Lazar, Hornberger, & 
Spiegel, 1997; Mumford, Schlesinger, Glass, Patrick, & Cuerdon. 1984). Outcome studies meet 
many needs. Mirin and Namerow ( 199 I) affirmed that "Treatment outcome studies, although 
difficult to design and carry out, are essential in demonstrating the efficacy of psychiatric 
treatmenc, rationalizing clinical decision making, and encouraging public support for the 
availability of appropriate, cost-effective care for the mentally ill" {p. 1007). 
Outcome assessment has been used to evaluate the length of treatment needed. This use of 
outcome assessment has been disputed for some time. Strassberg, Anchor, Cunningham and 
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Elkins ( 1977) wrote "Mental health practitioners are increasingly under fire by consumer 
advocates and others to demonstrate the value of their services. A central issue in this debate 
concerns the optimal length (many vs. few sessions) of counseling" (p. 477). The issue of 
treatment duration became more than a debate when the rising healthcare costs of the early I 980's 
led to the era of accountability and managed mental health care systems (Wells, Burlingame. 
Lamben. Hoag. & Hope, 1996). 
At the same time, changes within both mental health and health insurance companies have 
contributed to a trend toward time-limited therapy which seems to have begun in the early 80's 
(Gyorky, Royalty, & Johnson, 1994). In 1992 the Joint Commission on the Accreditation of 
Healthcaie Organizations {JCAHO) moved to the Continuous Quality Improvement model which 
required that ongoing monitoring of patient care and improvement be added to the existing 
outcome assessment procedures (Burlingame, Lamberl, Reisinger. Neff, & Mosier, 1995). This 
model has helped some practitioners to increase their effectiveness. 
More recently, the mental health field's understanding has gained depth concerning the 
impact of psychotherapy on individuals. Gabbard et al .. ( 1997) wrote 
ln the last decade or so, the emphasis in the mental health field has shifted away from cost 
offset to a more complex understanding of the economic impact of psychosocial 
interventions. One factor in this shift has been the recognition that the concept of cost 
offset tends to ignore the effects of psychiatric disorder on the quality and quantity of life. 
Inherent in the concept of cost offset is the notion that treating mental illnesses is only 
beneficial because it reduces overall costs of medical care. (p. 147-148) 
Since that time. treatment outcome has come to mean different things for different groups. Lowry 
and Ross ( 1997) wrote "discrepancies may also be attributable to differences in outcome 
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criteria used by therapists (i.e., clinically significant change), third-party payers (i.e., medically 
necessary), and clients (i.e., symptom relief)" (p. 276). Despite this, everyone seems to agree that 
the need for accountability, and the practical constraints of applied science drive current outcome 
assessment efforts (Lambert et al., 1998). 
Treatment and Cost Management 
Practitioners have been frustrated by this trend and the increasing emphasis on cost 
management. Psychologists have complained of a decline in emphasis on quality health care and a 
loss of decision making capacity. These changes have now affected psychotherapists working in 
mos! settings. Schaeffer ( l 998) wrote "Finding effective and economical interventions in brief 
therapy has become a challenge for therapists of all orientations needing 10 make noticeable 
progress within a short period and to achieve positive, measurable outcomes" (p.14). 
Some psychologists have proposed that the over-emphasis on cost containment be stopped 
and clinical decision making be returned to the psychologist. Mirin and Namerow (1991) wrote 
"The mental health industry must now assume responsibility for developing its own cost-
containment suategies, lest others in the executive and legislative branches of government, as well 
as in the private sector, develop them independently" (p. 1007). In fact, these limitations are being 
imposed already. A limit of 10-20 outpatient mental health visits per year is standard and enforced 
by many managed care organizations and state/federal agencies of mental health care (Lowry & 
Ross, 1997). 
Wells et al. ( 1996) reminds readers that for most practitioners, tracking psychotherapy 
outcomes is becoming a requirement, not an option. This requirement not only stresses the 
efficacy of treatment but the importance of documentation of treatment decisions based on 
treatment outcome studies. Burlingame et al. (1995) wrote "it is essential for health care 
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providers to document clinical results (endpoint assessment) and employ procedures for 
identifying and correcting problematic components of treatment through continuous ongoing 
monitoring of patient care (i.e., continuous quality improvement [CQI])" (pp. 226-227). These 
procedures have already been demanded for some time. Lambert and Brown ( 1996) wrote 
The wholesale purchasers of health care services (employers, insurance companies, 
government) are increasingly demanding that measurement of clinical outcomes be 
incorporated into all aspects of health care delivery, and that treatment decisions are made 
based on sound empirical evidence for efficacy and value rather than financial 
considerations alone. (p. 176) 
Regardless of new requirements to track patient progress in psychotherapy, there is a 
growing realization among practitioners of the need to set themselves apart as professionals. ln 
this regard, Lambert. Ogles. and Masters ( 1992) wrote "Whereas the charlatan relies on selected 
case testimonials to justify using marginal treatments, the professional counselor understands his 
or her ethical obligation to provide objective evaluation of the quality of service" (p. 527). 
Treatment decisions are likely to be most appropriate when they originate with the service 
provider. Lowry and Ross (1997) stated "psychologists are guided by professional ethics to 
provide a necessary and sufficient amount of psychotherapeutic intervention to adequately treat a 
client's problem(s)" (p. 272). The goal of improvement of services can only aid in the process of 
ensuring future practitioners' management of their care. increased quality of care, based on 
effective interventions, will allow therapists to regulate treatment conditions better and avoid 
third-pany payment struggles. Johnson and Shaha ( 1996) wrote 
Developing quality improvement models allows professional psychology to undo the 
disastrous mistakes of the past of opposing managed care (psychology's opposition to 
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managed care only marginalized the profession and certainly did not contribute to any 
resolution of the problems with managed care). Continuous Quality Improvement will 
promote effective treatment options based on results of treatment. (p. 227) 
Low-cost systematic measurement of treatment effects by the practitioner will establish a basis for 
treatment decisions made by him or her. 
In addition to the above, managed care has put brief intervention models at the forefront of 
treatment modalities. This emphasis on cost-effective therapy is not all bad, however, and can be 
used to provide prescriptive treatments that bring lasting change. Even psychologists agree that 
1here are some problems that can be effectively treated in relatively few psychotherapy sessions. 
Lowry and Ross ( 1997) wrote 
The findings suggest that situational (e.g., work difficulties, adjustment disorder) or 
symptom-based (e.g., sleep problems, simple phobia) problems are expected to require 
significantly less psychotherapeutic intervention than relational problems or personality 
problems. Moreover, disorders typically viewed as biologically based (e.g .. schizophrenia) 
were considered as requiring the largest number of psychotherapy sessions or were 
considered untreatable by psychotherapy alone. (p. 276) 
Some clients feel that less counseling is preferable and sufficient (Warner, 1996). In such 
cases, service providers can limit the number of sessions needed to reduce symptoms and ensure 
gains. Salzer, Bick.man, and Lambert ( 1999) affirmed that "the relationship between number of 
outpatient psychotherapy sessions and clinical outcome has become a focus of attention" {p.235). 
This kind of approach is crucial if future therapists want to market their skills effectively. Going 
beyond "good-enough therapy," this type of patient-service considers the cost of treatment and is 
more responsible for it. 
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Client attrition, dosage limits, and average length of treatment have all been considered 
when making ueatment decisions. Phillips (1988) wrote "Today, more and more psychotherapists 
think in terms of planned short-term treatment--whether using a 6-session (the most common). 16-
session, or 26-session mode" (p. 669). Treatment duration decisions have also been influenced by 
client diagnosis. therapist theoretical orientation, therapist age, experience, and gender (Lowry & 
Ross. L 997). Furthermore. since many patients terminate so early in treatment, service providers 
need to weigh carefully the amount of psychotherapy they recommend. 
The concern of many practitioners is whether or not brief therapy will be intentionalized 
(Steenbarger. l 992). The number of sessions prescribed must always be in the best interests of the 
patients and must consider the patients' willingness and commitment to treatment. This can 
become quite difficult with certain disorders. Franko and Erb ( 1998) wrote 
The challenge of treating patients with eating disorders, together with the increasing 
intrusion of third-party payers into the healthcare system presents a dual dilemma for 
mental health clinicians. Although there are potent treatments for patients with anorexia 
nervosa and bulimia nervosa, most therapies require substantially more than a brief 
number of sessions in order to be effective. (p. 43) 
Patients' mental health needs, symptom severity, risk, as well as financial means to pay for 
treatment are a few of the factors that need careful consideration when treatment recommendations 
are made. Often, clients are highly aware of their problems and are ready to form an alliance with 
practitioners (Steenbarger, 1994). These clients can collaborate with their therapists to make some 
decisions about the duration of treatment. 
Service providers also need to inform their clients about treatment alternatives and 
expected positive and negative outcomes, as well as recommend what is the best course of 
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1rea1men1 for them. A s1udy done by Consumer Reports showed that clients who stayed in therapy 
more 1han six months reported the most progress and those who began therapy with more serious 
problems reported the best outcomes after staying in therapy for two years (Gurin, 1995). 
Seligman ( 1995) wrote about the results of the Consumer Reports study, "Long-term therapy 
produced more improvement than short-term therapy. This result was very robust, and held up 
over all statistical models" (p. 968). As symptom severiry increases, clinicians and third party 
payers must be open to more treatmem. As has been staled above, ongoing assessment of 
treatment ou1comes can help practitioners increase their effectiveness and maintain control over 
treatment decisions. Lambert and Brown ( 1996) wrote 
There is no doubt that standardized monitoring of patient progress will further 
demonstrate the value of psychotherapy and lead to greater understanding of just how and 
when it is most and least effective. We look forward 10 the time when clinicians routinely 
and sys1ematically gather and share information about the effects of their work, blending 
the best of the art and science of psychotherapy. (p. 177) 
[mprovement over Various Durations 
Other studies have looked at the percentages of patients improved for various amounts of 
psychotherapy. Howard, Kopta, Krause, and Orlinsky, (1986) wrote 
By eight sessions. 48% to 58% of patients would be expected to have measurably 
improved. About 75% of patients should have shown measurable improvement by the 
end of six months of once-weekly psychotherapy (26 sessions) and about 85% by the end 
of a year of treatment. (p. 162) 
One study of the benefits of differing doses of psychotherapy on college students found that 11 % 
of the college students reported improvement on interpersonal relations after 2 to 5 sessions, this 
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increased, however, to 38% for those completing 11 to 20 sessions (Weitz et al., 1975). 
Furthennore, the length of therapy has been found to be a significant predictor of improvement. 
particularly for the less severe mental and emotional conditions (Knesper, Belcher, & Cross, 
1987). 
Another study of clients seen at a college counseling center found a strong linear 
relationship between the proportion of clients improved and treatment length up to about 20 
sessions (Strassberg et al., 1977). Salzer et al. ( 1999) stated that dose-effect studies such as the 
ones above have had a tremendous influence on the mental health field and have encouraged other 
dose-effect studies. If clinicians or managed care organizations are rigid about lengths of time for 
treatment, some clients may never get the help they need. One study surveyed l,000 members of 
American Psychological Association Division 29 (Psychotherapy) and found psychologists 
expected 30 to 40 sessions of individual psychotherapy to achieve clinically significant change 
(Lowry & Ross, 1997). 
As can be seen from the above-mentioned studies, many clients need more than eight 
sessions co demonstrate measurable improvement. For example, Steenbarger ( 1994) has found in 
his review of brief therapy that 
Clients who are highly aware of focal problem patterns and fonn a ready, involving 
alliance may benefit from symptom-centered, prescriptive interventions that achieve their 
goals within 8 to 10 sessions. Within this group and over this limited span, there appears 
to be a strong relationship between duration and outcome, and considerable evidence that 
enduring changes can be achieved. At the other end of the continuum, clients with 
broad, diffuse, and poorly understood patterns and who need considerable time to form a 
trusting alliance may benefit from an extended period of exploratory work that moves 
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treatment to the limits of brevity and beyond. (p. 116) 
This seems to support cost management when clients are appropriate for briefer therapy. and. at 
the same time. supports therapists trying to best meet the needs of their clients when larger 
amounts of psychotherapeutic interventions are needed. One study found that even general 
functioning increased with a longer duration of therapy. Seligman ( 1995) wrote 
The advantages of long-term treatment by a mental health professional held not only for 
the specific problems that led lo treatment, but for a variety of general functioning scores 
as well: ability to relate to others. coping with everyday stress, enjoying life more. personal 
growth and understanding, self-esteem and confidence. (p. 969) 
There is a current need for ongoing research in psychotherapy dose-effects. The need for 
increa~ed quality of services dictates that practitioners learn from the services they provide and 
seek 10 better customize interventions. Information can be shared with other providers to ensure 
maximum effectiveness of treatment and the avoidance of premature discontinuation or excess 
where not needed. Herron, Eisenstadt, Javier, and Primavera ( 1994) wrote "If session 
effectiveness research becomes more extensive, sophisticated, and comparable, it could be a 
valuable tool for more informed decisions by policy makers, funders, consumers, and providers" 
(p. 284). 
The trend toward managed care involvement in decisions must alert practitioners to 
continue to seek effective interventions and psychotherapy amounts. Franko and Erb (1998) stated 
In reality, most [insurance] plans offer four to eight sessions and the authorization of 
additional visits requires a substantial crisis or life-threatening behaviors. Therapists are 
required to manage patients in increasingly less time and are pressured by third-pany 
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payers to do so or risk being denied further referrals. (p. 44) 
Measuring treatment efficacy across visits will increase as third-party payers seek to maximize 
their service-to-cost ratio (Umphress, Lambert, Smart, Barlow, & Clouse, 1997). 
It seems certain at this point that the very diversity of challenges that face therapists will ensure no 
one appropriate dose for all. Steenbarger ( 1994) wrote "The present review raises the possibility 
that there is no one function linking duration and outcome across all clients, concerns, and helping 
approaches" ( 117). 
Brief Therapv 
It is difficult to study dose-effects of psychotherapy without being impacted by brief 
therapy. This treatment model seems to be the goal of many of the funders of mental health 
services. Limits on insurance coverage for psychotherapy have always existed (Herron et al.. 
1994) and so this should not alarm us. ln fact, financing problems of health insurance companies. 
a growing demand for psychotherapy, and the restricted number of psychotherapists have all 
contributed to the development of short-term psychotherapies and their standardization (Kordy, 
Von Rad, & Senf, 1988). Brief ueatment models have also gained support from clinicians who 
need to stay on provider panels and demonstrate cost effectiveness to managed care organizations. 
At times, even patients seem to advocate for brief therapy. "Spontaneous remission" seems 
to illustrate this. Howard et al., (1986) wrote "Our meta-analysis suggests that about 15% of 
patients will feel and/or show measurable improvement before attending the first session of 
psychotherapy" (p. !63). Many times situational or symptom-based problems can be treated 
effectively in a relatively short duration. Because brief therapy has been, at times, unfairly 
compared with other treatment modalities of longer duration, it has been viewed as lesser by some 
practitioners. Steenbarger (1992) wrote 
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Given that brief therapy is viewed as less effective than time-unlimited treatments for most 
clients, it would not be surprising if therapists tended to underestimate the effects of such 
work relative to the ratings of clients and neutral observers. This. in fact, appears to be 
the case. (p. 54) 
This is unfortunate as brief therapy can be an effective intervention for various problems. Herron 
el al. ( 1994) wrote "Given a particular goal, such as symptom removal, brief psychotherapy may 
do as well or beuer than unlimited psychotherapy. That does not mean that shon-term and long-
term therapies are interchangeable or that they have identical results" (p. 283). 
In summary, outcome studies have been a part of mental health l.l'eatment for a long time 
and have been used for a variety of reasons. Recently, changes within both mental health and 
health insurance companies have contributed to the use of outcome studies to investigate the issues 
of treatment duration and the quality of patient care. The practitioners who deliver these services 
seem to be both frustr:ited and stimulated by these challenges and would like to demonstrate a high 
degree of professionalism in these matters. Therapists are also concerned that brief therapy will be 
imentionalized for reasons of cost containment and the best interests of the patient will be 
secondary. As for the literature in this area, many studies have supported !he efficacy of 
psycho1herapy and the benefits of it in larger amounts for some patients while other studies have 
found brief l.l'eatment to be sufficient for problems such as symptom removal. It seems that short-
lerm and long-term therapies serve unique functions for distinct populations. 
Given the inconsistencies in the research findings regarding the effectiveness of time-
limited therapy. the author decided to conduct an outcome study of varying amounts of 
psychotherapy. It is necessary to understand dose-effects so that treatment decisions can best be 
made. ethical standards can be met, and quality of service can increase. Specifically, the aim of 
Dose-Effect Relations 12 
this study was to investigate the effects of varying doses of psychotherapy given over a I 0 week 
period to undergraduate students who served as analog psychotherapy patients. These varying 
doses of psychotherapy were the independent variables in this study. The dependent variables 
were the symptoms of the participants in the study as they reported them on the OQ-45.11. 
Four research questions were addressed by this exploratory study. First. what, if any, is the 
rate of change in reponed symptoms by a group of "normal" undergraduates exposed to IO 
sessions of psychotherapy? Second, if the psychotherapy does reduce the subjects' symptoms, are 
I 0 sessions more effective than 5 at doing so? Third. is there a linear relationship that can be seen 
for the effect of the psychotherapy on the subjects' symptoms? Fourth, did gender affect the 
outcome within the treatment group. and, if so, in what way? 
Hypotheses 
Three hypotheses were tested in this study: (I) Subjective Well-Being scores (as measured 
by the Outcome Questionnaire-45.11) for the treatment group will be significantly lower than 
those of the control group on the mid and post-tests. (2) Subjective Well-Being scores will be 
lower for the treatment group subjects tested after five, and ten sessions of individual 
psychotherapy than the scores of the same subjects on the pretest. (3) Subjective Well-Being 
scores will be lower for the treatment group subjects tested after ten sessions than the scores of the 




Dose-Effect Relations 13 
Participants included college student volunteers serving as analog individual psychotherapy 
clients for first-year students in a doctoral clinical psychology program. The sample of 60 students 
was taken from a Northwest university. Ages ranged from 18 years to 20 years. The gender 
composition was approximately 56% female and 44% male with most of the participants being 
Caucasian. The participants tested were currently enrolled in an Introduction to Psychology class 
and received research credit for their participation in the individual psychocherapy. 
The experimental group was fonned by taking the weekly schedules provided by the 
participants interested in the psychotherapy. giving them to the graduate student trainees, and 
having the trainees contact participants whose schedules would aHow the trainees to meet with 
them on a weekly basis. The control group was fonned by asking the students of 4 Introduction to 
Psychology classes to take the Outcome Questionnaire-45.11 and other measures. Although the 
Religious Orientation Scale and an Experimental Measure of Religious Practices were also 
administered, this study did not utilize those data. Research credit was provided for those students 
who compleced the measures all three times. They were administered over a twelve-week period. 
Measures 
Treatment effects were assessed by means of the OQ-45. l L The OQ-45.11 is a 45-item 
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measure that includes items that assess subjective discomfon, interpersonal relationships, and 
social role performance (Burlingame, Hansen, Larnben, Lunnen, & Umphress, 1994). These areas 
represent how persons feel, how they are getting along with significant others, and how they 
are doing in imponant life tasks such as work and school (Burlingame et al., 1994). Each item is 
responded to on a five point Liken continuum from Never to Almost Always. The OQ-45.11 
measures patient progress in therapy and was designed to be repeatedly administered during the 
course of treatment and at termination. Gross treatment assignment decisions can be made from 
the OQ-45. l l as it was designed to be used as a baseline screening instrument. Nonna! scores for 
Undergraduates on the OQ-45.11 are: Subjective Distress - 23.08, Interpersonal Relations - 8.95, 
Social Role - 10.37, and Total - 42.4. 
The OQ-45.11 was chosen for this study over other measures for its brevity (taking one-
half the time of similar measures), its breadth of use, as well as its sensitivity to change over short 
periods of time while maintaining high levels of reliability and validity (Wells et al.. 1996). The 
co-efficient for internal consistency of the OQ-45.11 Total score is .93, and the test-retest 
reliability is .84. The co-efficients for validity are .7824 with the General Symptom Index of the 
Symptom Check List-90-Revised, .7959 with the Beck Depression Inventory, .8625 with the 
Taylor Manifest Anxiety, and .6449 with the Social Adjustment Scak. 
The OQ-45. 11 is a broad measure as well, designed to assess common symptoms across a 
wide range of mental disorders and syndromes including stress related illness and V. codes 
(Burlingame et al., 1994). Although the OQ-45.ll is a face-valid test, and could be distorted 
consciously, the participants would have received no benefit from doing so. 
Procedure 
The participants for the treatment group were selected by the graduate students 
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conducting the psychotherapy. The graduate students were told to select one female and one 
male participant to ensure counseling experience with each gender. The graduate students chose 
panicipants whose schedules were similar to theirs so !hat finding times to meet together would be 
easily facilitated. Of the participants left in the sample, 62 were assigned to the control group as 
they had completed the OQ-45.11 all three times it was administered. Twenty-three of the 
participants served in the treatment group with similar numbers of males and females in each 
treatment and control group. 
The participants were given the OQ-45.11 three times: 1) before beginning psychotherapy, 
2) after five sessions, and 3) following ten sessions of psychotherapy. The measure was given to 
the treatment and the control group participants by their Introduction to Psychology instructors all 
three times. The participants were selected out of 4 classes taught by 4 different instructors. 
lnfonned consent was collected by the instructors during the first administration of the measure. 
All participants were selected, treated, and tested within a twelve-week time frame to minimize 
"history" effects. 
Participation in the study was voluntary. Participants were given information regarding 
involvement in the testing and how the experience may have affected their treatment. Because 
assessment was done in the classroom and not overtly linked with the treatment, the experience of 
the testing is expected to have little, if any, effect on treatment. Participants were instructed that 
no negative repercussions would result from declining to participate except that the treatment 
group would not receive research credit if they did not complete the psychotherapy. Attempts 
were made to encourage all of the participants to remain in the study. 
The participants were assured anonymity and confidentiality of all responses. Each 
participant was given a number. All data was identified by tile number only. The author kept the 
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master list of names and numbers as well as all consent fonns. When all the data was collected, 
the list of names and numbers was destroyed. Participants were told that all responses were for the 
purposes of "training a graduate student in clinical psychology." Participants were given the 
option to discontinue at any point. 
Directions for completing the OQ-45.11 are printed on the answer sheet. The test 
administrator(s) encouraged the participants to fill out the scale in an honest and conscientious 
manna and complete all items. The average time required for taking the OQ-45.11 is less than ten 
minutes. 
The treatment process consisted of the trainees meeting with their client one time per week 
for fifty minutes. The trainees were first year graduate students and were using basic counseling 
skills rather than a particular therapeutic orientation. The focus was on attending, listening, 
understanding, basic empathy, probing, summarizing, challenging, and helping clients plan and 
work for what they wanted. The manual that was used to train the graduate students for this 
experience was Exercises in Helping Skills, (6th ed.) by Gerard Egan (1998). 
The trainees were supervised by either the professor teaching the counseling skills class or 
one of two graduate assistants. The supervision hour consisted of groups of three trainees meeting 
with their supervisors and sharing audio or video recordings of themselves with a client. They 
were asked to share instances of themselves demonstrating specific skills as well as difficulty and 
success at helping the client. A critique of the skills and ideas for further work with the client was 
shared by the supervisor. 
Statistical Analysis 
The above-mentioned three level design utilized an analysis of variance with repeated 
measures to test for the significance of the independent variable, psychotherapy (Brase & Brase, 
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1995). The data was read into SPSS and descriptive data was used co make group and occasion 
comparisons. A 2 X 3 multivariate analysis of variance with repeated measures (treatment vs. 
control groups, pre, five week and ten week outcomes) was used to compare this data. 
Chapter 3 
Results 
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Of the l 35 participants who completed the OQ-45 .11. 57 ( 42%) failed to complete it all 
three times: 48 of these 57 participants were in the control group and were removed from the 
study. The remaining 9 were in the treatment group and l of the 9 was removed from the study as 
he/she had failed to take the OQ-45. l l during either the first or second administration. An 
additional treatment group participant was not included in the study as he/she was referred for 
additional treatment. Of the 23 participants in the treatment group, 10 (43%) were male and 13 
(57%) were female. Of the 62 participants in the control group, 28 (45%) were male and 34 (55%) 
were female. 
The OQ-45. l l is a screening measure that includes item~ assessing subjective discomfort, 
interpersonal relationships, and social role performance. It yields scores for subjective distress, 
interpersonal relations, social role, and has a total score. These four scores provided the data to be 
analyzed. Figures 1-4 represent each of these domains at the pre-test, mid-test and post-test for the 
treatment groups. Descriptive statistics for each of the main variables are included in 
Table I. 
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Table I 
M~ans illld Stillldar~ Deyfati2~ QD OQ4S, 11 fQc I~llD!:Dl and C201ml GUU.!l!li b)'. Oci;asi2os 
Variable Group Gender Mean Standard Deviation N 
Symptom Treatment Male 26.75 16.lO 8 
Distress I Female 29.63 12.00 8 
Total 28.19 13.80 16 
Control Male 25.50 8.11 28 
Female 23.44 7.37 34 
Total 24.37 7.72 62 
Total Male 25.78 I0.14 36 
Female 24.62 8.62 42 
Total 25.15 9.31 78 
__ .......... -.. ------------------... ---------·--------·-----·-----
Symptom Treatment Male 25.75 12.68 8 
Distress 2 Female 27.38 12.32 8 
Total 26.56 12.10 16 
Control Male 25.93 9.58 28 
Female 22.21 7.69 34 
Total 23.89 8.73 62 
Total Male 25.89 10.15 36 
Female 23.19 8.82 42 
Total 24.44 9.49 78 
----------·--------------·------------------------------·-··-
Symptom Treatment Male 29.00 17.08 8 
Distress 3 Female 26.75 l 1.49 8 
Total 27.88 14.ll 16 
Control Male 25.79 9.52 28 
Female 20.82 8.03 34 
Total 23.06 9.01 62 
Total Male 26.50 l 1.41 36 
Female 21.95 8.94 42 
Total 24.05 10.34 78 
-------------------------
Table Continues 
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Table l Continued 
Variable Group Gender Mean Standard Deviation N 
Interpersonal Treatment Male 10.88 7.75 8 
Relations I Female 10.38 4.60 8 
Total 10.63 6.16 16 
Control Male 10.46 5.24 28 
Female 7.24 3.83 34 
Total 8.69 4.77 62 
Total Male 10.56 5.76 36 
Female 7.83 4.12 42 
Total 9.09 5.10 78 
---------------------------------·----------------... --.......... - ..... ------·------------------
Interpersonal Treatment Male 13.00 9.32 8 
Relations 2 Female 8.25 5.06 8 
Total 10.63 7.65 16 
Control Male 9.46 4.83 28 
Female 6.79 3.07 34 
Total 8.00 4.15 62 
Total Male 10.25 6.13 36 
Female 7.07 3.51 42 
Total 8.54 5.12 78 
-----------·--------------------------------------------
Interpersonal Treatment Male 11.25 9.22 8 
Relations 3 Female 10.25 5.28 8 
Total 10.75 7.28 16 
Control Male 9.39 4.89 28 
Female 6.88 3.21 34 
Total 8.02 4.21 62 
Total Male 9.81 6.0l 36 
Female 7.52 3.85 42 
Total 8.58 5.06 78 
----------------------------------------------------------
Social Treatment Male 10.50 3.16 8 
Role 1 Female 11.38 3.96 8 
Total 10.94 3.49 16 
Control Male 11.04 2.63 28 
Female 8.59 3.41 34 
Total 9.69 3.30 62 
Total Male 10.92 2.72 36 
Female 9.12 3.64 42 
Total 9.95 3.35 78 
----------------------------... ------------
Table Continues 
Dose-Effect Relations 23 
Table I Continued 
Variable Group Gender Mean Standard Deviation N 
Social Treatment Male 11.25 2.82 8 
Role2 Female 9.75 3.58 8 
Total 10.50 3.20 16 
Control Male I 1.18 3.69 28 
Female 8.71 3.23 34 
Total 9.82 3.64 62 
Total Male 11.19 3.48 36 
Female 8.90 3.28 42 
Total 9.96 3.54 78 
----------------------................. -------------------------------------------·-----------
Social Treatment Male l l.88 4.91 8 
Role 3 Female 12.25 3.24 8 
Total 12.06 4.02 16 
Control Male 11.71 3.11 28 
Female 7.91 3.04 34 
Total 9.63 3.60 62 
Total Male 11.75 3.51 36 
Female 8.74 3.49 42 
Total 10.13 3.79 78 
----------------------------·--------------·-------
Total I Treatment Male 48.13 25.90 8 
Female 51.38 18.91 8 
Total 49.75 21.97 16 
Control Male 47.00 13.52 28 
Female 39.26 12.87 34 
Total 42.76 13.62 62 
Total Male 47.25 16.59 36 
Female 41.57 14.75 42 
Total 44.19 15.78 78 .......................... _________________ ... _________________________________ 
Total 2 Treatment Male 50.00 23.65 8 
Female 45.38 18.83 8 
Total 47.69 20.79 16 
Control Male 46.57 15.26 28 
Female 37.71 12.45 34 
Total 41.71 14.38 62 
Total Male 47.33 17.14 36 
Female 39.17 13.95 42 
Total 42.94 15.93 78 
..... -----------------------------·-------
Table Continues 
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Table I Continued 
Variable Group Gender Mean Standard Devialion N 
Total 3 Treatment Male 52.13 28.26 8 
Female 49.25 17.47 8 
Total 50.69 22.74 16 
Control Male 46.89 15.15 28 
Female 35.62 13.02 34 
Total 40.71 15.01 62 
Tola! Male 48.06 18.48 36 
Female 38.21 14.76 42 
Total 42.76 17.20 78 -----................................... _________________________ .. _______________________ .. .,. ___________________ ,. ______ 
The first research hypothesis concerned how 10 sessions of psychotherapy would affect 
the rate of reported symptoms of a group of undergraduates. An analysis of variance with 
repeated measures revealed no significant treatment effects across ad.ministrations of the 0Q-
45.11. There were no significant group effects when the treatment group was compared to the 
control group at the pre-therapy, f(l,74)=2.996, 12.=.088; and post-therapy testings, 
.E( l,74)=1.605, 12.=.209; and oo significant occasion effects. f(l,74)=1.751, p.=.190. However 
the lnterpersonal Relationships scale was close to significance, f(l,74)=3.553, 12.=.063; and a 
significant gender effect was observed, f(l,74)=4.029, J;!.=.048. No time (occasion) by group 
interactions were found, f(I, 74)=.988, 12.=.324; and no ume by group by gender interactions. 
(E(2,148)=3.404; 12.=.036). 
The second research hypothesis investigated the differences between the treatment group's 
symptoms at pretest and at 10 sessions. No main effects for treanneot were found, f(l,19)=.140, 
12.=.712. Chi-square analyses were performed and the Interpersonal Relationships scale, 
.E(l, I 9)=3.446, ~.079, was near significance. The Subjective Distress scale, f(l, 19)=1.069, 
~.314; Social Role scale, E(l,19)=2.165, ~.158; and Total scale, f(l,19)=2.073, w.166 were 
Dose-Effect Relations 25 
not significant. 
The third research hypothesis addressed whether or not there was a linear relationship that 
could be seen for the effect of the psychotherapy on the subjects' symptoms. An analysis of 
variance with repeated measures again revealed no significant treatment effects across 
administrations of the OQ-45.11, f(l,19)=1.999, I!=.174. 
The final research hypothesis was interested in gender and if it would affect the outcome 
within the treacment group. A 2 X 3 multivariate analysis of variance with repeated measures 
revealed that there were no main effects for participants' gender. However, when time was 
compared to group and gender, a significant linear effect for time by gender interaction was found 
on the Subjective Discomfon scale, f( 1,74)=5.56, 2.=.022; and significant quadratic effects were 
found on the Interpersonal Relationships scale, f(l,74)=5.379, 2.=.023. for time, group, and 
gender. Significant quadratic interactions were also found for time by group by gender for 
Interpersonal Relationships, .E=6.568, 2.=.012, and for Social Role, f=4.372, I!-=.040. Results of 
analysis of variance for each of the main variables are included in Table 2. 
Tre~tment Groups Compared 
There were no differences found between participants in the treatment group who 
completed the OQ-45.11 all three times and those who did not on the Subjective Discomfort scale, 
f( I, I 9)=1.069, Q.=.314; Social Role Performance scale, f(l,19)=2.165, Q.=.158; or Total scale, 
.E< t, t 9)=2.073, 2=.166. Although there were no significant group effects found when the two 
treatment groups were compared, there were three quadratic effects and interaction effects found, 
time by gender for Interpersonal Relationships, f(l,19)=5.379, I!=.023; time by group by gender 
for Interpersonal Relationships, f( l, 19)=6.568, X?=.012; time by group by gender for Social Role, 
E< I, l 9)=4.372, £!:;:.040; and time by gender for Subjective Disuess. 
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Table 2 
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Sample Means Compared 
Students t tests measured whether the sample means differed from the nonnative means 
and the results are included in Table 3. There were no differences found between the normative 
means for normals and the sample means. 
Table 3 
Results oft Tests Comparinii Sample Means wjth Nonnatjye Means from the OQ-45 I I 
Measure Normative Mean Sample Mean Significance 
Symptom Distress 23.08 25.15 l.648 NS 
Interpersonal Relations 8.95 9.09 .208 NS 
Social Role 10.37 9.95 .976 NS 
Total 42.33 44.19 .887 NS 
Chapter 4 
Discussion 
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ln general. the results of this analog study of treatment effects do not support the 
hypothesis that Subjective Well-Being scores of the treatment group would be significantly higher 
than those of the control group on the mid and post tests (Hypothesis 1). There was no significant 
group effect when the treatment group was compared to the control group at the pre-therapy and 
post-therapy testings and no significant treatment effects across administrations of the OQ-45. l l. 
Symptoms were found to be unchanged at the end of the testing or post administration for all the 
participants. It is unknown what accounts for these effects. One cause may have been the 
semester that the student panicipants were in. They may have been affected by the spring break 
that took place near the mid-test. The end of the semester may have also increased their feelings 
of subjective distress as finals were soon to be taken. 
Furthermore, both the treatment and control subjects were taken from an analog sample. 
The scores of the treatment and control subjects were all normal, and this may have reduced the 
amount of possible treatment effects before the independent variable, psychotherapy, could be 
administered. It seems that this study needed a clinical sample to administer the psychotherapy to 
for treatment and control groups. 
Hypothesis 2 was not supported by the results either. Subjective Well-Being scores were 
not higher for the treatment group subjects tested after five, and ten sessions of individual 
psychotherapy than the scores of the same subjects on the pretest. A 2 X 3 multivariate analysis 
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of variance with repeated measures revealed no significant treaunent effects. Again, this may have 
been a result of using a non-clinical analog sample for the treatment group. The treatment groups' 
symptoms were not very high to begin with (pretest symptoms) and so clinically significant change 
was difficult to attain. 
The results of this study do not support hypothesis 3 that Subjective Well-Being scores will 
be higher for the treatment group subjects tested after ten sessions than the scores of the same 
subjects after five sessions. An analysis of variance with repeated measures again revealed no 
significant treatment effects across administrations of the OQ-45.11. Time was found to not be a 
significant variable a-; there were no overall simple linear effects. 
Gender was also found to have no effect on the outcome within the treatment group. A 
2 X 3 multivariate analysis of variance with repeated measures revealed that the participants' 
gender did not predict outcome. However, when time was compared to group and gender, there 
were interaction effects. lt is not clear what may have caused this. Interestingly, there was a 
quadratic effect on the lnterpersonal Relationships scale and a quadratic effect was found. 
indicating a time by group by gender interaction on the Social Role Performance scale. 
Treatment Groups Compared 
The results of this study do not support differences between participants in the treatment 
group who completed the OQ-45.11 all three times and those who did not. Chi-square analyses 
were performed and the Interpersonal Relationships scale approached significance. Although there 
were no significant group effects found when the two treaunent groups were compared, there were 
three quadratic effects and interaction effects found. 
One interesting finding was that the participants in the study indicated a very similar 
response to item #17, "I have an unfulfilling sex life." While the majority of the participants 
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marked "Never" as their response, many of them wrote a note next to the item that indicated they 
do not participate in sexual behavior. As most all the participants are not married, this common 
response seems to point to the behavioral health of the sample. Perhaps this sample is not only 
non-clinical, it may be considerably healthy. The treatment group was pulled from this sample and 
their self-report symptoms were quite low as they began the psychotherapy. Reducing symptoms a 
significant amount in persons that are already in a healthy range is very difficult. 
Compariso::i of Normative and Sample Means 
When a Student's t-test was used 10 compare the means of the nonnative sample of 
undergraduates to this sample at pretest on the four scales no differences were found. This may be 
a result of comparing one relatively healthy group to another. It is likely that both of these 
undergraduate samples represent groups of people with very few clinical symptoms. 
Limitations 
Although this current investigation attempted to understand the significance of dose-effect 
relationships in psychotherapy, several limitations of this study should be considered. The 
graduate student conducting the research served as a direct supervisor of the first-year doctoral 
students and his participation in the research may have affected psychotherapy outcomes in the 
college students. In addition, the first-year doctoral students' psychotherapy experience was varied 
and so may have had an unknown effect on the outcomes. 
Perhaps the most significant limitation in the present study was the sample. Specifically, 
the treatment group was an analog sample of mostly healthy college students. This might have had 
the effect of limiting the amount of symptoms that could be reduced. For treaunent effects to be 
demonstrated a significant amount of change is necessary; the notmal pre-treatment scores of this 
sample made it difficult to measure any effects of the independent variable, psychotherapy. 
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Another limitation of this study might be in its specificity. The sample of undergraduate 
general psychology students at George Fox University may not represent the young-adult 
population as a whole. Participants in this study were largely Caucasian. Given the religious 
nature of the instimtion, we can assume that the majority of the panicipants were Christians. Due 
to their faith, many of the participants may not engage in substance abuse, sexual indiscretions, or 
hnve thoughcs of ending their life. All three of these issues appear on the OQ-45. l l (five times) 
nnd can affect one's overall score of sympcoms. 
These results apply to self-referred college students who had been offered class 
credi! for their participation in the study. Results might differ in outpatient clinics. hospitals or 
other non-academic settings. Finally, this study pertains only to the dose-effect relationship in 
ndult psychotherapy. and the results may not generalize to child psychotherapy. 
Suggestions for Future Research 
Treatment outcome studies are essential to clinical decision making and guaranteeing cost-
effective care (Mirin & Namerow, 1991 ). The issue of treatment duration and optimal length has 
become a central focus recently. The present study attempted to address this issue, but the power 
of the study was diminished by the sample. Future dose-effect studies may benefit from taking 
their treatment group from a clinical sample. Using a more diverse sample would also be a better 
representative of the greater population. A larger sample would increase the power of the 
stmistical tests. 
Many scudies described their favorite length of therapy and could cite much research to 
substan!iate their views. For example, some have used the Consumer Reports study to make a 
case for a longer duration of treatment (Gurin. 1995). It seems as though treatment duration has 
become political and the studies being done are to back up ones' views and not to find what is best 
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treatment. It would be best if those who conduct dose-effect studies would be open to more or 
less therapy for any particular problem and would avoid seeking to prove a particular treatment 
duration is optimal. 
Conclusion 
Although this study did not support the hypotheses that were established, it did provide 
valuable insights on how and how not to conduct a dose-effect study. The study reminds us of 
the value of a sample and how a analog sample can limit the possibility of clinically significant 
change. It is difficult and time-consuming to conduct treatment outcome studies. I hope that this 
study will encourage others to pursue treatment outcomes. As a result, mental health 
professionals will be better equipped to make treatment decisions in a professional manner. 
It is recommended that future studies use a larger sample. Having the first-year students 
in the doctoral clinical psychology program counsel three or four college student volunteers per 
week would make that possible. It is also recommended that the study examine whether the 
analog therapy experience contnbutes to increased reporting of symptoms. The final 
reconunendation is that the participants be split into a group of normals and clinicals at the outset 
of the study. 
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Informed Consent 
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Informed Consent for Participation 
------- understand lhal I am participating in a research project for lhe training of a 
graduate student in clinical psychology. As a participant, I will be given the Outcome 
Questionnaire (OQ.45.11) three times. In addition I will be given several survey questions rhat ask 
about my attitudes and beliefs related lo social and religious beliefs and behaviors. I undersrand 
that I may discontinue my involvement in the research at any time. I also understand that all data 
will be kept confidential and only the graduate student conducting the research (Brian Whitehall) 
and the faculty members involved in the research, Dr. Rodger Bufford and Dr. Kathryn Ecklund 
will have access to my research data. I understand that there will be no reference to my name on 
any of the testing material. I will be assigned a number by the graduate student conducting the 
research who will protect my evaluation data from being attached to my name at all rimes. 
Signature of participant:-------- Date: ___ _ 
Participant Identification Number (to be placed on participant forms) ____ _ 
Appendix B 
Data Code 
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Data Code 
Identification: columns 1-3 
Sex: column 4 - Male - L. Female - 2, Missing data - 9 
Group: column 5 - Treatment - I, Control - 2 
column 6 & 7 - leave blank 
Scores: columns 8-33 
SD l - column 8&9 
lRl - column 10&1 l 
SRI - column 12&13 
Total l - column 14& 15 
Blank column 16 
SD2 - column 17 & 18 
lR2 - column 19 & 20 
SR2 - column 21 & 22 
Total:? - column 23 & 24 
Blank column 25 
SD3 - column 26 & 27 
IR3 - column 28 & 29 
SR3 - column 30 & 31 
Total3 - column 32 & 33 
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The model is a repeated measures design and all data for a given participant are entered in 
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Raw Data 
25291 99999999 21141247 29131557 
l 0711 13070323 99999999 23040835 
14411 2311l246 2710124931051349 
21411 1204 !026 17051436 17102047 
17611 140205211405072611030519 
18121 22091041 16050728 26081145 
2071 l 49261287 49301392 55231795 
21821 08020616 1003072099999999 
30221 39091159 43101265 29061348 
16821 21090939 17040930 17071135 
16921 09030517 110305 l 9 99999999 
05421 I 1040520 17101138 99999999 
09511 541816884125158155281396 
14911 26031140 15020926 99999999 
17121 49181986 42161573 44161979 
1251 l 15080932 22101143 18090936 
05121 29050943 22060836 99999999 
18221 2303 1440 25041140 99999999 
09821 39091664 37071155 40141468 
17721 14060828 11020619 09071127 
18721 32170958 28150548 28190855 
l 7411 27091147 l 7111038 25041039 
2051 l 20090938 19080835 20080836 
2092 l 2 I 060936 25071345 21051137 
09311 34100953 30090746 99999999 
12911 99999999 99999999 99999999 
08192 99999999 3 l !01354 35071355 
13022 32 !00648 29110646 27100946 
14022 24091043 23071545 16050728 
13322 26060638 30081149 25070638 
14612 2007 l l 38 23061039 11060926 
14822 15031028 27091046 99999999 
12722 23090537 l !030519 07030515 
13612 19121142 22071342 22060937 
11922 24080840 24081042 22070837 
13512 391813705415178652111780 
I 0112 21080938 20081038 18031132 
11712 34121561 3512146139081360 
13212 26161153 2712115021101243 
12312 22081040 22091142 22091041 
12122 351411603212115599999999 
12422 25060637 17060528 18060529 
07922 31100748 29091048 26090944 
20112 17060528 14060828 14080729 
04422 331008513108094826070740 
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03912 39200968 38251174 99999999 
21322 15050828 15030624 15090529 
04712 21081140 29061045 28091451 
08812 150313319999999999999999 
08022 I !020619 09040417 06010310 
05812 06070720 29121051 99999999 
08322 12070524 13060322 99999999 
06512 22110942 14030724 22110841 
13922 43201679 37161669 99999999 
10212 38211978 41211880 99999999 
l 1322 21080938 20050833 24100842 
04112 45211783 99999999 42181474 
03812 38171065 37201067 41241580 
20222 l405l l30 l5l20835 19081037 
21122 38151366371ll15940101161 
21222 18041032 99999999 19060833 
21522 24060939 16040727 15040928 
21022 35041756 30061652 28091148 
12822 17050628 99999999 99999999 
13 122 20061036 17031030 99999999 
07712 12030722 12031328 99999999 
07622 18090835 11050521 06030110 
04822 25110945 26090944 22120943 
07822 22101244 99999999 31141055 
08712 33181263 27191056 99999999 
07422 17040627 22040935 13020621 
05522 l408093 l 99999999 99999999 
08912 391312644315167441131266 
08512 28041244 20040731 27050840 
05612 12060725 17110836 99999999 
05212 19030628 21040934 99999999 
09212 22050532 23040835 25080841 
10022 24100943 24091144 23081142 
08422 28070843 99999999 99999999 
09722 13040926 99999999 28100846 
08222 53161180 99999999 99999999 
091 12 14040725 99999999 99999999 
04222 20030629 22061139 15061132 
20822 15030422 09020516 10010415 
22022 24050837 19090836 21070634 
12612 17090834 99999999 99999999 
11612 240611412211104327081348 
14712 20050833 28050942 19031133 
14222 26101349 26071447 27070741 
11812 14061030 12091031 15110632 
09412 33161059 99999999 99999999 
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05712 16091237 1913144699999999 
05322 11050420 16030524 14030421 
07322 39171672 39111464 27101249 
09912 23201154 99999999 99999999 
21922 42131772 99999999 33131965 
06222 27091450 28091249 25091549 
05922 19030426 13050220 15040625 
12022 41181372 43191476 99999999 
15012 34211772 30162369 23121752 
06722 35171062 99999999 43191072 
06812 04010611 99999999 03050715 
06912 33171363 35031351 30111455 
06412 40111364 32091354 26081044 
20412 13191345 13150937 24091548 
10422 11040419 99999999 99999999 
20312 20091241 31181766 24081547 
04922 14001024 16021028 14050928 
l 0522 21061037 2205 1138 99999999 
16212 15090933 15070729 17071034 
16722 27141152 99999999 21051036 
16312 37191470 34121157 33121358 
16012 34180860 99999999 3012095 l 
16122 24091346 99999999 99999999 
18312 22021135 20041236 15041231 
165 12 27061043 25060738 22061341 
18522 20060632 22050835 31060946 
18412 23111448 23150846 25090943 
15822 26030635 22030833 22060533 
18812 24071041 23081243 39241780 
13822 15030523 24050837 28070944 
143::!2 05020411 050104 LO 99999999 
14522 34071253 31111153 99999999 
17822 20081038 22080838 28081248 
04022 28121353 24110843 18090835 
06622 21041035 99999999 22051037 
19522 20050833 99999999 25091044 
17222 25141251999999992716ll54 
18022 33121257 34131057 35161263 
21612 22080737 99999999 12070625 
09012 36141565 30151055 99999999 
20692 99999999 99999999 40151469 
21792 99999999 99999999 25120946 
05192 99999999 99999999 29100645 
05092 99999999 99999999 14040927 
03792 99999999 99999999 38211574 
Dose-Effect Relations 44 
Appendix D 
Vita 






Brian J. Whitehall 
5881 Batterman rd. 
East Wenatchee, WA 98802 
Home: (509) 884-4572 
sllabetihw@.wl.com 
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Graduate School of Clinical Psychology: APA Accredited 
George Fox University, Newberg, Oregon 
Student in clinical psychology Psy.D. program 
Graduate School of Clinical Psychology 
George Fox University, Newberg, Oregon 
M.A. in Clinir.al Psychology 
Western Baptist College 
Salem, Oregon 
B.S. Psychology 
Supervised Clinical Experience 
7/99-6/00 Cliniail lnternsbip 
Northeastern Ohio Universities College ofMedicioe: APA Accredited 
1/00-6/00 Portage Path Behavioral Health. Akron. OH. 
Population: Adults 
Duties: lndividual Therapy and Intake Interviews. Co-facilitated a Dialectical 
Behavior Therapy group, a Partial-Hospitalization group, and a 
Tramitiooal Support group. Developed treatment plans and worked with a 
multi-disciplinary treatment team. Comprehensive assessments of 
adults (Coguitive/IQ, Personality, and Cbaracterological ). 
Supervisor: fm Mullen, Ph.D. 
7 /99-12199 Massillon Psychiatric Center, Massillon, OH. 
Population: Chronically Mentally ill Adults 
Duties: Interviewed new patients and wrote evaluations. Individual Therapy. 
Led a Stress-Management group and co-f.acilitated a Dialectical Behavior 
Therapy group. Provided recommendations to multi-disciplinary treatment 
team. Wrote treatment plans for patients with the psychiatrist. 





Practicum Ill {Total Hours: 400) 
Lutheran Family Service, McMinnville, OR. 
Population: Adults, families, children 
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Duties: Individual and Family Therapy. Co-facilitated two violence 
prevention groups for men. Conducted intakes, provided treatment 
recommendations and consulted with agency psychiatrist. Personality 
assessment and therapy for low-income children and adolescents in an 
outpatient setting. 
Supervisor: Susan Means, Ph.D. 
Practicum II (Total Hours: 533) 
Oregon State Hospital, Salem, OR. 
Population: Chronically Mentally ill Adults 
Duties: Comprehensive assessments ofinpatienl adults with emphasis on 
neuropsychological assessment (Cognitive/IQ, Psychosocial, 
Characterological, and Neuropsychological). Individual and Group 
Therapy (Drug and Alcohol, Symptoms Management with emphasis on 
psychiatric rehabilitation). Risk assessment and screening process for a 
forensic, minimum custody unit. 
Provided ~omm:ndations to multi-disciplinary treatment team. 
Supervisor: Brett Rogers, Ph.D. 
Practicum I (Total Hours: 642) 
Linn County Child and Family Services, Albany, OR 
Population: Adults, fiunilies, children 
Duties: Individual and Family Therapy. Co-fucilitated anger management 
group for adolescents and their families in an outpatient mental health 
clinic. Comprehensive psycbologic:al assessmenrs of children and 
adolescents primarily presenting with ADHD, Conduct Disorder, or 
SexuaJ Abuse at intake. 
Supervisor: Paul Stoltzfus, Psy.D. 
Prepractieom (Total Hours: 75) 
George Fox University, Newberg, OR. 
Population: Aduhs 
Duties: Provided counseling to two undergraduate students. 
Received clinical training including: clinical skills, psychosocial 
assessment/hi.story, mental status exam, intake interview, treatment 
plans, anger management, and critical inr.ident response. 
Supervisor. Wayne Colwell. Ph.D. 
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Other Work Experience 
7/97-8/98 Mental Health Therapist Technician (Total Hours: 1,464) 
Oregon State Hospital, Salem, OR. 
Population: Adolescents, children 
Duties: Paid Position. Counseled and assisted children and adolescents with 
major mental illnesses. Docwnented on the treatment and progress of 
patients. Problem-solved with co-workers regarding treatment decisions 
and milieu management. 
Supervisor: Enuna Alstott RN. 
Research Experience 
l 0/97-present Diss.-!rtation 
Title: Dose-effect relations in simulated psychotherapy as measured by the 
outcome questionnaire-45 .11. 
Description: A treatment outcome study, this research examines the efficacy of 
psychotherapy under varying doses, on the subjective well-being of University 
students. 
Chair: Rodger Bufford, Ph.D. 
Status: Fina! Oral completed. Making final changes. 
Anticipated date of completion: 3/0 I 
2/98-5/98 Program Development 
Assisted with development, implementation and consulting report 
assessing faculty student relationships at George Fox University. 
Teaching Experience 
9/97-4/98 Graduate Assistant (Total Hours: 227.5) 
Wayne Colwell, Ph.D. 
PSY 530 Prepracticum Didactic 
Duties: Paid Position. Assisted in the training of fourteen graduate 
students. Taught basic assessment and counseling skills, ethics, 
and self-awareness. Led two supervision groups, provided 
feedback and evaluations to trainees. 
PSY 531 Prepracticum Didactic 
Duties: Paid Position. Provided supervision to seven graduate student 
counselors providing individual therapy to undergraduate 
students. Taught continuing development of counseling skills, 
interventions, referrals, case conceptualization, and tennination. 
Provided feedback and evaluations to trainees. 
Professional Affiliations 
American Psychological Association (Student Affiliate) 1994-present 
Professional Seminars 
I 0198 Using The 16PF In Clinical Practice 
Michael Karson, Ph.D., ABPP 
5198 Race And Racism In Psychotherapy 
Alice Chang, Ph.D. & Nelson de Jesus, Ph.D. 
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4/98 Explicit, Implicit, Intentional Clinical Integration: Galileo and Wesley: Two old, 
but ever-new integration models. 
Newton Malony, Ph.D., ABPP 
J/97 REBT 
Albert Ellis, Ph.D. 
I 0196 False Memory 
L Polanski, Ph.D. 
4/96 Brief Therapy: Object Relations 
Greggory, Hamilton. M.D. 
4/96 Narcissistic Disorders 
Ralph Klein, M.D. 
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Adolescence, Adulthood, and Aging 
Learning 
Legal, Ethical, and Professional [ssues 





Systems of Psychotherapy 
Community Mental Health 
Abnormal Psychology 
Clinical Theory and Practice: 
Psychodynamic Psychotherapy 









Human Sexuality/Sexual Dysfunction 
Psychophannacology/Psychoneurology 
Therapy with Women 
Forensic Psychology 
Group Dynamics 
Child/ Adolescent Therapy 
Geropsychology 
Psychodynamic Integration Seminar 
Clinical Assessment 
Personality Assessment 
Cognitive and Intellectual Assessment 
Projective Assessment 
Neuropsychological Assessment 
Comprehensive Psychological Assessment 
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